Nos complace anunciar que Legit.Health asistirá al 52º Congreso Nacional de Dermatología y Venereología (AEDV), que se celebrará del 7 al 10 de mayo de 2025, en Valencia, España. Esta es una oportunidad fantástica para conocer de primera mano cómo nuestras soluciones de inteligencia artificial y visión artificial están transformando el diagnóstico y la gestión de las afecciones cutáneas.

Programa de presentaciones y pósteres​

Durante AEDV 2025, nuestro equipo presentará sus investigaciones y avances a través de charlas, simposios y comunicaciones orales. Consulta el programa a continuación:

Nota: Recomendamos estar atentos a cualquier actualización oficial de la agenda respecto a cambios de sala o horario para AEDV 2025.

Agenda una reunión con nuestro equipo​

¿Estás interesado en ver una demostración de nuestra herramienta o aprender cómo implementar la IA en tu clínica?

Reserva una reunión con nosotros durante el congreso para descubrir todo lo que Legit.Health puede hacer por ti.

Recordando 2024​

En 2024, presentamos nuestra investigación sobre el impacto de Legit.Health en el diagnóstico y la derivación en afecciones dermatológicas en atención primaria. Los resultados fueron prometedores, mostrando una mejora significativa en la precisión diagnóstica y una reducción en las derivaciones innecesarias.

Legit.Health participará en el Congreso de la Academia Europea de Dermatología y Venereología (EADV) 2025 en París, del 17 al 20 de septiembre.

Durante el evento presentaremos cuatro pósters científicos que muestran cómo la Inteligencia Artificial clínicamente validada está transformando la dermatología en una disciplina más eficiente y centrada en el paciente.

Nuestro trabajo demuestra cómo la IA puede reducir la variabilidad, ahorrar tiempo en consulta y extraer endpoints objetivos tanto en la práctica clínica como en ensayos clínicos.

Nuestros estudios aceptados​

Por qué esto es importante​

Legit.Health está redefiniendo el abordaje de la dermatología al proporcionar herramientas útiles y clínicamente validadas con IA que transforman tanto la práctica diaria como la investigación.
Estos hallazgos subrayan la relevancia de nuestra innovación: convertir evaluaciones complejas y subjetivas en endpoints objetivos, reproducibles y escalables.

La alianza estratégica combina la experiencia mundial de QuantifiCare en imagen médica con la inteligencia artificial líder de Legit.Health para acelerar el desarrollo de nuevas terapias en dermatología.

En un gran avance para la investigación dermatológica, QuantifiCare y Legit.Health anunciaron el lanzamiento de la primera plataforma que combina imagen e inteligencia artificial para ensayos clínicos en dermatología.

La dermatología abarca un amplio espectro de enfermedades. Sin embargo, en ocasiones puede existir un foco desproporcionado en las afecciones malignas como el melanoma y los cánceres de piel no melanoma. Este enfoque pasa por alto la importante carga global de otras afecciones dermatológicas, que superan con creces a las enfermedades malignas.

El melanoma es una enfermedad muy importante a considerar. Nadie lo niega. Es una enfermedad maligna con una alta tasa de mortalidad. Sin embargo, comprender la prevalencia real de las afecciones dermatológicas es crucial.

Prevalencia real de las afecciones dermatológicas​

Aunque las malignidades suelen destacarse en dermatología, representan solo una pequeña fracción del total de afecciones dermatológicas. El siguiente gráfico de pastel ilustra la distribución de varias enfermedades dermatológicas:

%%{init: {'theme': 'base', 'themeVariables': { 'pie1': '#04af65', 'pie2': '#e5edea', 'pie3': '#8671ff', 'pie4': 'red', 'pie5': '#eae8f7', 'pie6': 'gold', 'pie7': '#505050'}}}%%

pie title
    "Enfermedades infecciosas" : 57
    "Otras condiciones" : 19
    "Enfermedades inflamatorias" : 15
    "Enfermedades malignas" : 5
    "Enfermedades autoinmunes" : 3
    "Genodermatosis" : 1
    "Enfermedades vasculares" : 1

Desglosemos estas categorías para comprender su importancia y la necesidad de una cobertura integral en dermatología.

Enfermedades infecciosas (57%)​

Las enfermedades infecciosas de la piel representan la categoría más grande a nivel mundial, comprendiendo aproximadamente el 57% de las afecciones dermatológicas. Las infecciones fúngicas constituyen alrededor del 34%, las infecciones bacterianas alrededor del 23% y las infecciones virales como el herpes zóster y las verrugas genitales también contribuyen significativamente[^1].

El propósito de este informe es evaluar la idoneidad de dos modelos de smartphone Samsung, A16 y A05S, para aplicaciones de teledermatología, centrándose en su capacidad para capturar imágenes de alta calidad de lesiones cutáneas con facilidad y fiabilidad.

Resumen Ejecutivo​

Ambos modelos cumplen los requisitos técnicos para teledermatología, pero el Galaxy A16 es mejor para el diagnóstico por imagen dermatológica.

La prueba en condiciones reales no reveló diferencias significativas, pero según el fabricante, el A16 tiene una cámara ligeramente mejor, un procesador más potente, una pantalla de mejor calidad y mayor soporte de software.

Sin embargo, ambos están muy por detrás del iPhone 16 Pro, que es aproximadamente 8 veces más caro pero ofrece una calidad de cámara y rendimiento general superiores.

Introducción​

La teledermatología implica el uso de imágenes para diagnosticar y monitorizar las enfermedades de la piel de forma remota, lo que hace esencial que los dispositivos rindan bien en escenarios específicos como:

• Capturar imágenes detalladas de lesiones no localizadas y pigmentadas bajo diversas condiciones de iluminación.
• Asegurar una calidad de imagen consistente para un diagnóstico preciso y medición de la gravedad.
• Apoyar los flujos de trabajo sanitarios integrándose perfectamente con tecnología de teledermatología, como Legit.Health.
• Proporcionar un rendimiento fiable durante el uso prolongado en entornos clínicos o de campo.

Estas tareas son críticas para dermatólogos y proveedores de atención sanitaria que buscan ofrecer atención remota efectiva y mejorar los resultados de los pacientes. Por esta razón, la elección del smartphone es crucial, ya que impacta directamente en la calidad de las imágenes capturadas para el análisis de lesiones cutáneas.

Estamos encantados de anunciar que Legit.Health ha obtenido oficialmente la certificación ISO 13485, marcando un hito significativo en nuestro camino hacia la excelencia en la industria de dispositivos médicos. Este logro no es solo un testimonio de nuestro compromiso con la calidad y la seguridad, sino también un reflejo de nuestra dedicación a cumplir con los más altos estándares internacionales.

¿Qué es la ISO 13485?​

La ISO 13485 es la norma reconocida mundialmente para los sistemas de gestión de calidad (SGC) específicos de la industria de dispositivos médicos. Desarrollada por la Organización Internacional de Normalización (ISO), esta norma garantiza que las organizaciones del sector de dispositivos médicos cumplan con estrictos requisitos regulatorios en cada etapa del ciclo de vida de un producto, desde el desarrollo y la fabricación hasta la entrega y las actividades postventa. La seguridad y la calidad no son negociables en la industria de dispositivos médicos. Con la creciente complejidad y las demandas regulatorias, la ISO 13485 sirve como un marco crítico para que las organizaciones demuestren su capacidad para proporcionar dispositivos médicos y servicios relacionados que cumplan consistentemente con las expectativas de los clientes y las regulaciones.

Introducción​

El futuro de la medición de la hidradenitis supurativa está aquí gracias al revolucionario AIHS4 (Sistema Automático de Puntuación de la Gravedad de la Hidradenitis Supurativa Internacional) de Legit.Health. Los investigadores han desarrollado una herramienta que procesa imágenes tomadas con cualquier camara y las analiza automáticamente usando los mismos criterios que el IHS4.

Nadie duda que las medidas de resultados objetivas, fiables y precisas son clave para la práctica de la medicina basada en la evidencia. En el caso de la hidradenitis supurativa, el IHS4 es la herramienta de medición más moderna y fiable, ampliamente recomendada para su uso en ensayos clínicos y práctica diaria. Por eso Legit.Health lo ha elegido como base para su nueva y revolucionaria tecnología.

Introducción​

La dermatología ha dado un gran salto adelante con la introducción del innovador ALEGI (Índice de Graduación de Lesiones de Acné) de Legit.Health. Los principales investigadores en el campo del deep learning y las redes neuronales se han aliado con dermatólogos expertos para desarrollar esta herramienta algorítmica médicos.

Está ampliamente aceptado que las medidas de resultados objetivas, fiables y precisas son clave para la práctica de la medicina basada en evidencia. A la hora de medir la gravedad del acné, esto implica el uso de escalas o sistemas de puntuación como IGA o GAGS. Por desgracia, en el caso del acné es especialmente difícil y tedioso utilizar los sistemas de puntuación más aceptados, ya que requieren que el médico cuente las lesiones manualmente.

Es por eso que Legit.Health ha desarrollado esta herramienta que cuenta el número y la densidad de las lesiones de acné. Gracias a ella, medir la gravedad del acné es una tarea que requiere solo segundos.

La siguiente captura de pantalla muestra un uso real del sistema de puntuación para el acné. Esto se puede utilizar tanto en móviles como en ordenadores de sobremesa.

La limitación de los sistemas tradicionales de puntuación del acné​

Desde que DM. Pillsbury y su equipo desarrollaron el primer sistema de puntuación para el acné en 1956, ha habido una miríada de intentos de encontrar un sistema fácil de usar, fiable y preciso para esta enfermedad. Hoy en día, existen más de 30 métodos, y todos ellos comparten uno de dos problemas subyacentes.

Introducción​

Los ensayos clínicos son el motor que impulsa la ciencia médica hacia adelante. Por eso, resulta intuitivo que las herramientas a disposición de quienes están a la vanguardia del progreso deben ser tan avanzadas y de última generación como la investigación en la que se trabaja.

La investigación que nos impulsará hacia el futuro no debería llevarse a cabo con herramientas del pasado, especialmente si aumentan la fiabilidad de los reported outcomes.

Legit.Health acepta el desafío de proporcionar a los investigadores una herramienta de inteligencia artificial útil y fiable para sus ensayos clínicos, mediante la incorporación de algoritmos de aprendizaje profundo y tecnología de análisis de imágenes en una interfaz fácil de usar y bien diseñada.

¿Cómo mejora Legit.Health los ensayos clínicos?​

Una buena manera de entender cómo se puede implementar la tecnología de Legit.Health en la investigación clínica para el desarrollo de medicamentos es escuchando la explicación de Diego Herrera. Diego es el Director de Datos Clínicos e Innovación Digital en Almirall.

Introducción​

El futuro de la medición de la urticaria está ahora al alcance de la mano. Medir la puntuación de la urticaria y las ronchas es más fácil y fiable que nunca gracias al revolucionario AUAS (Puntuación Automática de Actividad de Urticaria) de Legit.Health. Los investigadores han desarrollado una herramienta que procesa imágenes de smartphones y las analiza automáticamente usando los mismos criterios que el UAS7.

Es ampliamente conocido que las medidas de resultado objetivas, fiables y precisas son clave para la práctica de la medicina basada en evidencias. El UAS7 ha demostrado tener las mejores propiedades de medición y es el más recomendado para su uso en ensayos clínicos al considerar la urticaria.

UAS7: la base del diagnóstico de la urticaria​

La urticaria tiene una naturaleza muy variable, incluso cuando se convierte en una enfermedad crónica. Provoca erupciones que varían en intensidad y extensión, y los síntomas pueden variar de un momento a otro. Por esta razón, medir la gravedad es muy complicado. Para lograr este objetivo, el sistema de puntuación más utilizado para esta condición es el UAS7. De hecho, las guías internacionales EAACI/GA2LEN/EDF/WAO para la urticaria recomiendan el uso del UAS en la práctica clínica para determinar la actividad de la enfermedad y la respuesta al tratamiento.

El Urticaria Activity Score (UAS) fue desarrollado como un sistema de puntuación simple que tiene en cuenta el número de ronchas y la intensidad del picor. A pesar de que estas variables son registradas por los pacientes, muchos consideraron que su condición no podía ser descrita con precisión por el análisis aislado de su estado en un día.

Así nació el UAS7. El UAS fue creado en 2006 por un grupo de médicos liderado por un médico alemán llamado Torsten Zuberbier. También vino con una versión que agrega todas las puntuaciones UAS de un paciente durante siete días, lo que permite al médico entender mejor la extensión completa de la enfermedad.

Introduction​

The future of dermatology has arrived thanks to Legit.Health's revolutionary application of the PASI system: APASI (Automatic Psoriasis Area and Severity Index). Using computer vision algorithms, the researchers have created a tool that processes smartphone images and automatically translates them into the domain of the PASI.

It is widely known that objective, reliable, and precise outcome measures are key to evidence-based medicine. When considering psoriasis, the PASI has the best measurement properties and is the most recommended for clinical trials. That is why we automated the PASI to help patients and doctors achieve better health outcomes.

The origins of the PASI​

This scoring system for psoriasis was first published in a paper by T. Fredericksson and U. Pettersson in 1978, where they explored the validity of a new treatment for the disease.

Legit.Health ha sido validado clínicamente en diversos entornos sanitarios por especialistas líderes en sus campos. Nuestra tecnología ha demostrado su eficacia en la mejora del diagnóstico y el seguimiento, con estudios específicos centrados en ciertas patologías para evaluar la sensibilidad y la precisión.

Varios de estos estudios han sido publicados en revistas prestigiosas de dermatología, mientras que otros se encuentran en distintas etapas de publicación. Además, también proporcionamos evidencia clínica durante el proceso de certificación como dispositivo médico, algunas de las cuales no se han hecho públicas.

En Legit.Health, entendemos que recibir un correo electrónico inesperado sobre una nueva cuenta puede ser confuso y potencialmente alarmante. Este post está diseñado para aclarar qué significa cuando recibes una notificación de que tu proveedor de atención médica ha creado una cuenta para ti usando nuestra plataforma.

¿Qué es Legit.Health?​

Legit.Health es una plataforma médica avanzada utilizada por profesionales de la salud para mejorar la forma en que interactúan y gestionan la atención al paciente. Nuestra tecnología está diseñada para agilizar la comunicación entre tú y tu proveedor de atención médica, haciéndola más eficiente y efectiva.

¿Por qué recibí este correo electrónico?​

Tu proveedor de atención médica ha creado una cuenta para ti en nuestra plataforma para facilitar una mejor comunicación y gestión de tu tratamiento. Esto puede incluir acceso a registros médicos, programación de citas y herramientas de gestión de la salud que forman parte de tu plan de tratamiento.

Introducción​

Legit.Health presenta con orgullo un avance significativo en las evaluaciones dermatológicas: el sistema ASCORAD (Puntuación Automática de la Dermatitis Atópica SCOR). Esta herramienta innovadora aprovecha algoritmos avanzados de visión por computadora para analizar imágenes capturadas por smartphones y alinearlas automáticamente con el sistema de puntuación SCORAD.

El ASCORAD ha sido mencionado en publicaciones científicas recientes, como el siguiente artículo del Consejo Nacional de Investigaciones de Italia, y las Universidades de Palermo y Mesina:

(...) es muy prometedor el intento de llegar a una definición automática de la gravedad de la DA utilizando CNNs (...) para lograr una precisión de puntuación de eritema, papulación, excoriación y liquenificación comparable a la de los dermatólogos (...). Los avances aplicativos computacionales en esta dirección han llevado al diseño más reciente del SCOR Automático de la Dermatitis Atópica (ASCORAD).

De hecho, las herramientas de medición objetivas, fiables y precisas son fundamentales para la atención sanitaria basada en evidencias. La integración de ASCORAD en la suite de herramientas de Legit.Health representa un cambio de paradigma en cómo se evalúa y maneja la dermatitis atópica. Al automatizar el proceso SCORAD, ASCORAD no solo mejora la precisión y la fiabilidad de las evaluaciones, sino que también simplifica el flujo de trabajo para los profesionales de la salud, estableciendo un nuevo estándar para el cuidado dermatológico.

Introduction​

In the healthcare sector, a silent but pervasive challenge impacts the well-being of those at the frontline of patient care. This challenge is doctor burnout, a state of physical, emotional, and mental exhaustion caused by prolonged stress in the medical profession. The repercussions of doctor burnout extend beyond the healthcare providers; they also affect the quality of care received by patients.

At Legit.Health, we recognize the critical importance of supporting healthcare professionals. Our dedication to enhancing the lives of doctors and patients is reflected in our advanced artificial intelligence technology. Designed to streamline clinical workflows, our AI tools aim to alleviate the daily pressures faced by physicians, promoting a more sustainable work environment and better patient outcomes.

Doctor burnout, a serious problem​

Doctor burnout represents a significant and complex issue within the medical community. The World Health Organization defines burnout as an occupational phenomenon characterized by chronic work-related distress. It includes emotional exhaustion and irritability, a gradual loss of empathy and an increase in negative feelings such as cynicism, and a sense that your own professional effectiveness is rapidly decreasing.

Introduction​

Scoring systems are the unsung heroes of day-to-day dermatological practice. Disliked by many for the additional work they can bring to the table, they help train the clinical eye, bring a more evidence-based approach to the clinical practice and provide valuable endpoints in research.

There's no denying the crucial role scoring systems play in the development of the clinical field, as they are essential tools that bring precision, objectivity and reliability to clinical trials.

To better use and understand the tools at our disposal, we have to start at the beginning:

What is a Dermatological scoring system?​

In Dermatology, a scoring system is a methodology that allows the doctor to assess the severity of a condition by observing and quantifying objective parameters such as redness, the affected area, the quantity and density of lesions, and so on.

The main goal of a scoring system is to provide a tool that documents data precisely and consistently for routine evaluations and clinical studies.

Have you ever wondered how to deal with reimbursement when using Legit.Health? Let's explore why the act performed by our artificial intelligence is a reimbursable medical act.

Short answer: yes​

Yes, every time a patient sends a photo of their disease, and Legit.Health's artificial intelligence finds a disease or measures its severity, this constitutes a medical act, as defined in HL7's FHIR standard and the Medical Code of Ethics of most countries.

Keep in mind that Legit.Health's artificial intelligence searches for conditions and measures the degree of affectation of the patient on behalf of the doctor. Furthermore, there is a doctor indirectly involved in this process, who must confirm the diagnosis and make the final medical decision.

Read the paper​

We invite you to read the full paper for yourself, or you can scroll down to read the summary in this educational blog post.

Introduction​

We introduce AUAS, an automatic equivalent of UAS that deploys a deep learning lesion-detecting algorithm, called Legit.Health-UAS-HiveNet. Our results show that our algorithm assesses the severity of Chronic Urticaria cases with a performance comparable to that of expert physicians.

Years ago Andy Aguilar noticed something wasn't right with her skin. When she visited her doctor looking for a solution, she was met with an ordeal.

She was passed around from specialist to specialist, collecting incorrect diagnosis after incorrect diagnosis and taking the brunt of the consequences of the misguided treatments that came with them as her frustration with her healthcare providers grew.

Each new appointment with a new dermatologist came with its ever-extending waiting period as her symptoms worsened before her eyes.

After several years, many healthcare providers and six different dermatologists later, she found the diagnosis and treatment she needed, but rebuilding the trust in the healthcare sector took much longer.

Like Andy, thousands of patients all over the world face the same hurdle, feeling alone and forgotten by both the public and private healthcare sectors as their chronic condition worsens with each day.

The Edison Accelerator provides world-class business and technical guidance to EMEA startups.

MADRID, June 2021 - Five healthcare technology startups have officially upgraded into the first cohort of the Edison Accelerator in EMEA, a healthcare scale-up acceleration program designed by GE Healthcare in partnership with the innovation organization Wayra UK, Telefónica start-up accelerator.

Among the five start-ups that were chosen, there is a Bilbao company: Legit.Health, which is presented as a revolutionary clinical intelligence and communication tool that helps Next-generation dermatologists improve diagnosis, grade severity and monitor the evolution of chronic and malignant wound and skin lesions.

Introduction​

The real toll of a sanction for infringing the GDPR is magnitudes bigger than the mere financial cost, as it also affects the image of the company and erodes the trust that patients and employees have in the company.

This is especially true in the healthcare industry, where the trust and peace of mind of the patient are paramount for a successful business.

How can a medical centre shield itself against the many drawbacks of a sanction of this kind?

Healthcare provider Ribera Salud and Legit.Health started working together in one of the group's hospitals, the Torrejón Hospital, to implement the revolutionary algorithmic technology that, 2 years later, has shown excellent results.

In 2020, the healthcare provider Ribera Salud and Legit.Health started working together in one of the group's hospitals, the Torrejón Hospital, to implement the revolutionary algorithmic technology that, 2 years later, has shown excellent results thanks to the amazing job done by the doctors.

The pandemic could be a blessing in disguise, as it forced the teams to truly push the possibilities of remote care to new heights. In this particular case, the team at Torrejón Hospital needed to follow up on the patient's treatment but could not ensure all of them could go to the medical centre due to COVID-19.

Introduction​

At Legit.Health, our commitment to patients' wellbeing, both physical and psychological, takes us beyond focusing only on product features and algorithm performance. We know that our users are real people with real problems that are trusting us and their doctors, so we can help them overcome a disruptive condition.

This is why we want to outline the ways in which we are trying to improve the life quality of our users.

The ceremony attended by European technology executives aims to promote digital innovation.​

The European Patient Digital Health Awards (PDHA) ceremony, orchestrated by MSD — known for their innovation in COVID-19 treatment —, recently honored Legit.Health for its groundbreaking work in healthcare technology. Marking a significant milestone, Legit.Health is celebrated as the first Spanish company to clinch the PDHA award, a testament to its commitment to transforming patient care through digital innovation.

Over 60 contenders from 18 European countries were in the running, but it was Legit.Health's novel approach in dermatology that stood out. Their application, capable of identifying over 232 dermatological conditions through a simple smartphone photograph, impressed the jury, which included patient representatives and entrepreneurial experts. The honor specifically recognized their advancement in "New ways to interact with healthcare teams and providers".

The European initiative reinforced the vital role of innovation in healthcare and the evolution of technology, both for patients and for healthcare providers and professionals.

Alfonso Medela, a key figure at Legit.Health, brings personal experience to the table, having managed chronic urticaria since his youth. At only 26, he spearheaded the development of this tech solution, aiming to improve the lives of millions facing similar challenges.

Introduction​

The communication between doctor and patient is one of the cornerstones of modern medicine, after all, the patient is the only one who really knows about the full extent of the nature of some of their symptoms.

However, this seems to be something some doctors haven't yet mastered, and we think it is worthwhile to ask yourself...

Are you sure your patients understand you?​

When we try to imagine things in the medical practice that might go wrong and worsen a health problem or cause a new one, the most common cases to think about are surgery related infections, malpractice cases or accidents.

The Transformative Impact of Our AI-Driven Dermatological Technology on Society and Healthcare​

Since she was little, Andy Aguilar knew that many things were wrong with her skin. And when she needed doctors, she was met with an ordeal.

She was held back by primary care, and then passed around from specialist to specialist, collecting incorrect diagnosis after incorrect diagnosis and taking the brunt of the consequences of the misguided treatments that came with them as her frustration with her healthcare providers grew. Each new appointment came with its ever-extending waiting period, as her symptoms worsened before her eyes.

That's why she founded Legit.Health, based on her experience as a patient, and with first-hand knowledge of how to fix the system and rescue patients.

Addressing Critical Issues in Access, Timeliness, and Comprehensive Care​

By providing an efficient and highly accurate tool, our technology not only improves patient outcomes but significantly enhances the sustainability and equity of health systems globally. Indeed, our AI technology is not just about offering advanced diagnosis and monitoring capabilities. It's about transforming the patient experience by improving quality of life, enhancing health outcomes, empowering patients, and improving the overall efficiency of dermatological services. It's a comprehensive solution designed with a clear focus on patient-centric care.

Through the continuous tracking and analysis of these KPIs and metrics, we can assess the effectiveness of our AI technology in addressing critical healthcare issues and adjust our strategies as necessary for further improvements.

This collaboration will integrate Legit.Health's innovative technology into Aptar Digital Health's proprietary digital health platform to better manage and treat skin conditions

Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, today announced a new partnership with Legit.Health, an innovative artificial intelligence (AI)-based medical device (CE-marked) software company, which aims to transform patient care and increase patient adherence to better manage skin conditions.

Legit.Health's state-of-the-art technology, which supports the diagnosis of approximately 300 conditions, including atopic dermatitis, psoriasis and skin cancer, will be integrated into Aptar's Digital Health proprietary platform. Focused on enhancing patient care and increasing patient autonomy, this advanced digital solution will support healthcare professionals (HCPs) to diagnose skin conditions earlier and will enable patients to start sooner on treatment plans to improve their overall quality of life. The solution may also be used to facilitate patient enrolment in clinical trials.

Legit.Health's use of AI for monitoring disease progression through automated, clinically validated scoring systems such as the Psoriasis Area Severity Index (PASI) and SCORing Atopic Dermatitis (SCORAD) will be leveraged within this partnership. This will help to ensure patients receive the most accurate and timely information to manage and treat their skin condition more effectively. The AI-powered technology also extends to the quantification of the intensity, count and extent of the visible clinical signs of skin conditions, offering HCPs a more precise measure of disease severity, an indicator considered critical in determining the most appropriate treatment.

This strategic partnership is set to drive digital transformation in the healthcare sector. The combined expertise of Aptar Digital Health and Legit.Health will pave the way towards harnessing the power of AI to improve patient experiences and outcomes in immuno-dermatology.

As every year the Ship2B Foundation has recognized, with the seal of social enterprise impact, different startups and companies that develop innovations in the area of health. Among them is Legit.Health, an application capable of detecting skin cancer through a simple photograph taken with a mobile phone. The aim is to create a space to promote technological innovations that help to improve the health and quality of life of people.

This pioneering technology, already in use in several hospitals such as the Torrejón University Hospital in Madrid, is presented as a tool that uses artificial intelligence to improve the lives of doctors and patients, thus creating a better healthcare community. As Andy Aguilar, CEO of Legit.Health, and patient with several skin diseases says: "We use artificial intelligence with the aim of helping the doctor to perform tasks that can be automated so that he can focus on what is more important: the patient".

The creators of this application are 4 young people with chronic dermatological pathologies. Therefore, they have created the first tool capable of providing doctors with the necessary tools to help them help their patients. The Ship2B Foundation states that this mark recognizes companies that, like Legit.Health, persistently pursues an improvement in health and social welfare. And they seek to respond to current health issues by providing doctors with the tools they need to diagnose diseases that affect millions of people.

Introduction​

In recent years, society as a whole has started to get used to the inevitability of a fully digital world embedding itself in all aspects of life, including healthcare.

And although there are many benefits the applied practice of telemedicine brings, there are also challenges to overcome before we can start to reap the benefits of this novel way of understanding healthcare.

Dermatologists highlight the usefulness of images in remote monitoring of chronic pathologies. That is why the tool is still in use today in our care activity, and we continue to explore new uses and improvements to it in the future.

Telemedicine is a reality, not a prediction​

Digital disconnection is no longer a possibility for the average person. To this day and age, where every home has an internet connection and every pocket is laced with a smartphone, trying to deny the power the global net holds over our daily lives is as ridiculous as impractical.

2021 has been a pivotal year for Legit.Health. The company has grown tremendously out of its humble origins, adding to its roster talented and committed professionals that have put their all to make the next chapter of dermatology possible.

We have been rewarded and recognized for our work by several prestigious medical and business organizations, proving that the faith we put in a modern, value based, medicine is shared by many.

But most importantly, we have reached many more medical centres, and thus patients, all over Europe, allowing us to not only take part in numerous groundbreaking clinical trials, but to help doctors help their patients.

The pharmaceutical company and startup catalyst has been part of BHH 2021, a project that brings together innovations for the patients of the future.

The startup Legit.Health, in partnership with Novartis Biome, has demonstrated the importance of innovation and technology in the field of healthcare when it comes to saving lives, by participating in the Barcelona Health Hub Summit (BHH). An event that brings together innovative companies and products from all over the world, this year 2021 is the turn of technological innovations designed for the patients of the future.

Legit.Health application is capable of detecting the presence of 232 skin diseases through a simple image taken with a mobile phone, including skin cancer

One of the main objectives of Novartis Biome is to connect Novartis and the digital health ecosystem to bring innovative high-impact solutions to patients and healthcare professionals, acting as a catalyst for impactful digital collaborations, creating value that extends beyond medicines.

Introduction​

The future of skin cancer prevention has arrived thanks to Legit.Health's revolutionary pre-malignancy estimation tool.

Legit.Health has developed a clinically validated tool that processes smartphone images and automatically analyses them, utilizing the criteria of the top doctors in this field and calculating the pre-malignancy suspicion of any lesion.

All the advantages of cutting-edge technology and the processing power of deep learning algorithms are put in the hands of Next-Generation Doctors who want to prevent skin cancer.

Prevention should not consist on catching skin cancer before it kills you. Prevention should also catch a skin cancer before it's even skin cancer.

Skin cancer: common, lethal, ignored​

In a world where sunbathing and the use of tanning products and treatments have become widespread, the risk of skin-related diseases such as Keratinocyte cancer (which represents 95% of malignant skin tumours) is higher than ever.

Introduction​

The world is in a dire need of creating a more sustainable and efficient healthcare system that delivers value to its patients and improves the overall wellbeing of the entire community it serves.

Value-based healthcare may seem like a novel idea, but it has been around for more than twenty years, helping medical centres, pharmaceutical companies and insurance companies to have the greatest impact on patients while improving cost-efficiency in health care services.

What's Value-Based Healthcare?​

Value-Based Healthcare is a transformational concept whereby health care providers are compensated for the health and well-being of their patient population rather than for services rendered.

This paradigm shift began in the heavily privatized healthcare landscape of the United States of America, but has spread around the world over the past couple of decades, adapting to different systems and philosophies.

This renowned competition helps encourage projects in the healthcare sector and reminds us of the need to support innovation, very important in times of crisis and pandemia

The prestigious competition created in 2007 by Excellence Finland to promote innovative projects in companies and organizations, has awarded the startup Legit.Health with the Quality Innovation Award 2021 at the national level. A competition coordinated by the National Association of Excellence promotion Centers -CEX to give local and international recognition to the most innovative projects. Euskalit is one of the members of the Quality Innovation Award Committee, and in the local phase, it has the collaboration of Innobasque and Unibasq for the dissemination and evaluation of the candidatures.

Is the first time that a basque startup has been chosen in the health category, where all innovations aimed at the health sector are awarded. Legit.Health has been recognized for being a software for prevention, diagnosis, severity measurement and automatic monitoring of chronic and malignant skin diseases with artificial intelligence and computer vision algorithms.

The Spanish Artificial Intelligence startup Legit.Health and the health insurance company DKV join forces this summer to raise awareness around the dangers of skin cancer.​

Every year almost 23 thousands skin cancers are diagnosed in Spain.​

Summer is approaching and the cases of skin cancer are increasing. The good weather and high temperatures of the peninsula make many Spaniards go to the beach looking to show off their tanned skin. Forgetting, in many cases, the danger of prolonged exposure to solar radiation.

The revolutionary dermatology tool with Artificial Intelligence, Legit.Health, and the health insurance company DKV, know this very well. That's why they have decided to join forces to raise, among Spanish citizens and tourists, the importance of anticipating possible skin diseases and using teledermatology services.

Using what is already known as virtual dermatology, DKV offers, through the app Quiero cuidarme Más, all health services digitally on the phone. In short: it's an app that allows you to upload photos and virtually visit a dermatologist.

In an event that will be remembered as a turning point for dermatological science, the 48th congress of the Spanish Academy of Dermatology and Venereology (AEDV) in Bilbao was not only a gathering of minds but also a showcase of cutting-edge advancements in the field. A beacon of progress and resilience, this congress was the first major dermatology event in the post-pandemic era, illustrating the relentless pursuit of medical innovation.

Hosting over 300 global experts, this congress became a melting pot of ideas, fostering discussions on pivotal topics like psoriasis and teledermatology. Yolanda Gilaberte, vice president of the AEDV, highlighted the enhanced role of teledermatology accelerated by the pandemic, alongside the prospective transformations brought by artificial intelligence in skin disease identification.

Spotlight on Legit.Health: Advancing Dermatological Care​

Among the esteemed participants, Legit.Health emerged as a frontrunner in medical imaging, receiving accolades for its innovative use of deep learning algorithms in the "Automatic calculation of the Psoriasis Area and Severity Index (PASI)." This breakthrough underlines Legit.Health's dedication to enhancing patient care and revolutionizing the diagnosis and management of chronic skin diseases.

The Comillas ICADE Law School held the 1st Telemedicine Conference within the Uría Menéndez-ICADE Chair on Market Regulation. The Conference had the participation of representatives of the public and private sectors who have had the opportunity to review the situation of telemedicine in our country.

Relevant issues such as ethical, data protection and regulatory or responsibility aspects of telemedicine have been reviewed, concluding on the feasibility and necessity of the practice. Likewise, the essential public-private collaboration to promote the digitization of health has been highlighted as one more lever than those envisaged in the Recovery, Transformation and Resilience Plan financed with NextGenUE funds.